A bill to amend the Pharmaceutical and Medical Devices (PMD) Law is expected to be submitted to the ordinary session of the Diet this year, which was convened on January 17 for a 150-day run. The proposed amendment is for…
HOME > REGULATORY
REGULATORY
- Subcommittee to Study “Notification System” for Access to Unapproved Drugs
November 17, 2011
- PM Noda Says “Japan Will Not Lose” Public Health Insurance System in TPP
November 16, 2011
- Health Minister Komiyama Says “Government Position Recognized” in Iressa Case
November 16, 2011
- DPJ’s Medical and Nursing Care WT Discuss Promotion of Generic Drugs
November 16, 2011
- High Court Turns Down Iressa Compensation Appeal
November 16, 2011
- 7-Drug Rule Should Be Relaxed or Eliminated to Promote GE Name Prescribing: Dr Adachi of CSIMC
November 16, 2011
- Mr Sawai of JGA Opposes Reduction in NHI Prices of First Generics
November 16, 2011
- PAFSC Committee Recommends Classification of Isoconazole as Class 1 OTC Drug
November 15, 2011
- Merck Withdraws MAA for Sitagliptin, Pioglitazone Combination
November 15, 2011
- Former Health Minister Masuzoe Raises Drug Re-Pricing Issues Over TPP
November 14, 2011
- 2007’s “Emergency Proposal” for Distribution Reform Needs Review: Health Ministry Councilor Mr Takeda
November 11, 2011
- Discontinuation of Vaccination Following Death due to Unknown Cause Cannot Be Considered: David Salisbury, UK Director for Vaccines and Immunization
November 11, 2011
- MHLW Calls for Package Insert Revision for Bisphosphonates
November 11, 2011
- PMDA Draws Up "Global Vision" to Establish World Class Position
November 10, 2011
- MHLW Proposes Raising GE Dispensing Rates to Receive Upper Premiums for GE Dispensing Systems
November 10, 2011
- Mr Kobayashi of Kyokai Kenpo Proposes Measures to Promote GE Drug Use
November 10, 2011
- Applications for “Regulatory Strategy Consultation” Increasing Rapidly: Mr Isobe of PMDA
November 10, 2011
- Promote “Category-based” Negotiations Instead of Package Deals: Mr Hasegawa
November 10, 2011
- PAFSC Committee Approves Extension of Reexamination Period for DSP’s Lonasen
November 9, 2011
- MHLW Announces Add’l Indications Eligible for Applications Based on Info in Public Domain
November 9, 2011
ページ
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…
Japan’s all-important reimbursement policy panel on December 22 approved an outline of the next drug pricing reform scheduled for April 2022, which embraces plans to reward innovative new indications and introduce a grace period for so-called “spillover” re-pricing.The reform outline…
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…